1. Direktive 2001. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/directive-2001/83/ec-european-parliament-council-6-november-2001-community-code-relating-medicinal-products-human-use_en.pdf
2. Bundesinstitut für Arzneimittel und Medizinprodukte (2020) Lieferengpässe für Humanarzneimittel. https://www.bfarm.de/DE/Arzneimittel/Arzneimittelzulassung/Arzneimittelinformationen/Lieferengpaesse/_functions/Filtersuche_Formular.html?queryResultId=null&pageNo=0. Zugegriffen: 28.2.2020
3. European Medicines Agency (2019) Guidance on detection and notification of shortages of medicinal products for Marketing Authorization Holders (MAHs) in the Union (EEA)
4. Berg MJ, Gross RA, Tomaszewski KJ et al (2008) Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 71:525–530
5. LeLorier J, Duh MS, Paradis PE et al (2008) Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 70:2179–2186